FDA approves skin cancer vaccine by...?
As of Sun, 22 Nov 2026 18:29:17 UTC, Polymarket traders price December 31, 2027 (62.0%), September 30, 2027 (33.0%), June 30, 2027 (14.0%). The market has $234K in volume and closes on Sat, 01 Jan 2028.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| December 31, 2027 | 62.0% | 62.0¢ | 38.0¢ |
| September 30, 2027 | 33.0% | 33.0¢ | 67.0¢ |
| June 30, 2027 | 14.0% | 14.0¢ | 86.0¢ |
Market details
- Venue: Polymarket
- Volume: $234K
- Liquidity: $24K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for December 31, 2027:
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-001 will qualify. Approval for an indication other than melanoma will also qualify. Both standard and accelerated approval will qualify. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New…
Sources
Related markets
- Skin cancer vaccine BLA submitted by...?
- FDA approves Retatrutide this year?
- Which Millennium Prize Problem will AI solve next?
- SpaceX Starship fully reusable before 2027?
- Which math problems will AI solve in 2026?
- How many more Millennium Prize Problems will AI solve in 2026?
More markets like this
- Frontier AI lab pulls a model over safety concerns in 2026?
- Frontier AI labs announce joint pacing agreement in 2026?
- Gemini Carbon released on...?
- Gemini Carbon: HLE-Diamond Debut?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.